Moderna, Inc. (MRNA) stock is soaring 5.04% in intraday trading, as investors react to developments in the competitive RSV vaccine market. The surge comes as rival Pfizer secured expanded approval for its RSV vaccine Abrysvo in the European Union, highlighting the growing importance of RSV vaccines in the pharmaceutical industry.

While Pfizer's Abrysvo gained approval for use in adults aged 18-59 years in the EU, Moderna is not far behind in the race. The company's mRNA-based vaccine mResvia is currently under FDA review for expanded use in high-risk adults aged 18-59 years, with a decision expected by June 12, 2025. This pending FDA decision likely contributes to investor optimism, driving up Moderna's stock price.

The RSV vaccine market is becoming increasingly competitive, with Pfizer, GlaxoSmithKline, and Moderna all vying for market share. As Moderna continues to work on expanding its vaccine's use in both adult and pediatric populations, investors appear to be betting on the company's potential to capture a significant portion of this growing market. The stock's upward movement suggests that the market sees promising prospects for Moderna's RSV vaccine program, despite the intense competition.